AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NEUREN PHARMACEUTICALS LTD

22.460

-0.680-2.94%

Volume:552.37K

Turnover:12.46M

Market Cap:2.84B

PE:96.52

High:23.200

Open:22.800

Low:22.260

Close:23.140

52wk High:23.760

52wk Low:11.000

Shares:126.64M

Float Shares:108.39M

Volume Ratio:1.02

T/O Rate:0.51%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.233

EPS(LYR):0.233

ROE:8.67%

ROA:3.66%

PB:8.40

PE(LYR):96.52

Loading ...

Overview Company News Filings

Neuren Pharmaceuticals - Currently Reassessing Capital Management Options Including Continued Buyback Program and Commencing Franked Dividends

THOMSON REUTERS

Neuren Pharmaceuticals - to Confirm Outcome of Assessment in August, Decided to Pause Buyback

THOMSON REUTERS

Why Neuren Pharmaceuticals (ASX:NEU) Is Up 6.3% After Record DAYBUE Royalties And Strong STIX Launch – And What's Next

Simply Wall St.

Softer Q1 Results and Cash Returns Could Be A Game Changer For NewMarket (NEU)

Simply Wall St.

Stock Track | Neuren Pharmaceuticals Soars 5.12% Intraday as Daybue Stix Becomes Broadly Available in US

BRIEF-Neuren Pharmaceuticals Says Daybue Stix Now Broadly Available In US For Rett Syndrome

Neuren Pharmaceuticals Ltd - Daybue Stix NOW Broadly Available in US for Rett Syndrome

THOMSON REUTERS

Vantage Foundation and Banking Academy of Vietnam Launch Nationwide AI Finance Programme with Vietnam's Top Universities for More Than 1,500 Students and Educators

How Structural Oversupply In Petroleum Additives At NewMarket (NEU) Has Changed Its Investment Story

Simply Wall St.

Vantage Foundation and Banking Academy of Vietnam Launch Nationwide AI Finance Programme with Vietnam's Top Universities for More Than 1,500 Educators and Students

Neuren Pharmaceuticals (ASX:NEU) Is Down 15.2% After 2025 Earnings Undershoot Expectations Has The Bull Case Changed?

Simply Wall St.

Neuren's Royalties From Daybue Sales Beat Bull's Forecast -- Market Talk

Assessing Neuren Pharmaceuticals (ASX:NEU) Valuation After Its Latest Annual Earnings Reset

Simply Wall St.

BUZZ-Australia's Neuren Pharmaceuticals drops as US partner seeks EMA re-examination

Neuren Partner Plans to Request Re-examination of European Authority's Opinion on Trofinetide Marketing Authorization Application

MT Newswires Live

How Investors May Respond To Neuren Pharmaceuticals (ASX:NEU) 2025 Results, Buy-Back Plan And Pipeline Progress

Simply Wall St.

Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says

MT Newswires Live

Neuren Pharmaceuticals FY 2025 Margin Strength Tests Earnings Quality Concerns

Simply Wall St.

Neuren Pharmaceuticals Says US Partner Reports Higher Q4 2025 Daybue Sales; Shares Up 6%

MT Newswires Live

Is Neuren’s 5 Percent Share Buyback Altering The Investment Case For Neuren Pharmaceuticals (ASX:NEU)?

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/NEU.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NEU.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","market":"AU","secType":"STK","nameCN":"NEUREN PHARMACEUTICALS LTD","latestPrice":22.46,"timestamp":1787292720000,"preClose":23.14,"halted":0,"volume":552370,"delay":0,"changeRate":-0.029386343993085554,"nameEN":"NEUREN PHARMACEUTICALS LTD","floatShares":108394581,"shares":126639526,"eps":0.2327,"marketStatus":"Not Yet Opened","change":-0.68,"latestTime":"08-21 16:12:00 AEST","open":22.8,"high":23.2,"low":22.26,"amount":12461721,"amplitude":0.040622,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.2327,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787529600000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":23.14,"openAndCloseTimeList":[[1787270400000,1787292000000]],"volumeRatio":1.0189422128065255,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"NEU.AU","preClose":22.46,"auctionPrice":22.03,"auctionVolume":600,"auctionTime":1787518833561,"referenceTime":1787308204093,"auction":1,"marketStatus":"盘前竞价","timestamp":1787518833561}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","floatShares":108394581,"roa":"3.66%","roe":"8.67%","lyrEps":0.2327,"volumeRatio":1.0189422128065255,"shares":126639526,"dividePrice":0,"high":23.2,"amplitude":0.040622,"preClose":23.14,"low":22.26,"week52Low":11,"pbRate":"8.40","psRate":"44.00","week52High":23.76,"institutionHeld":0,"latestPrice":22.46,"eps":0.2327,"divideRate":0,"volume":552370,"delay":0,"ttmEps":0.2327,"open":22.8,"prevYearClose":18.61,"prevWeekClose":22.46,"prevMonthClose":18,"prevQuarterClose":17.75,"fiveDayClose":23.45,"twentyDayClose":16.46,"sixtyDayClose":13.8,"earningDate":1787673600000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NEU.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787702400000,"name":null,"time":"","dateTimestamp":1787666400000,"actualEps":null},{"date":"2025-02-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740697200000,"name":null,"time":"","dateTimestamp":1740661200000,"actualEps":null},{"market":"AU","date":"2024-02-29","symbol":"NEU.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1709125200000,"reportTimeType":"","actualEps":null},{"date":"2023-08-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693180800000,"name":null,"time":"","dateTimestamp":1693144800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NEU.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NEU.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2638857811","title":"Neuren Pharmaceuticals - Currently Reassessing Capital Management Options Including Continued Buyback Program and Commencing Franked Dividends","url":"https://stock-news.laohu8.com/highlight/detail?id=2638857811","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638857811?lang=en_us&edition=fundamental","pubTime":"2026-05-27 11:23","pubTimestamp":1779852237,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nFWN4230Y2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NEU.AU","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638578148","title":"Neuren Pharmaceuticals - to Confirm Outcome of Assessment in August, Decided to Pause Buyback","url":"https://stock-news.laohu8.com/highlight/detail?id=2638578148","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638578148?lang=en_us&edition=fundamental","pubTime":"2026-05-27 11:23","pubTimestamp":1779852237,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nFWN4230Y2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7508","NEU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634230366","title":"Why Neuren Pharmaceuticals (ASX:NEU) Is Up 6.3% After Record DAYBUE Royalties And Strong STIX Launch – And What's Next","url":"https://stock-news.laohu8.com/highlight/detail?id=2634230366","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634230366?lang=en_us&edition=fundamental","pubTime":"2026-05-12 03:30","pubTimestamp":1778527845,"startTime":"0","endTime":"0","summary":"In Q1 2026, Neuren Pharmaceuticals reported record net sales and more than 20% year-on-year royalty growth from Rett syndrome therapy DAYBUE, supported by Acadia Pharmaceuticals reaffirming full-year 2026 DAYBUE sales guidance of US$460–490 million.\nA key driver was the successful US launch of DAYBUE STIX, a new powder formulation that has seen strong uptake and high caregiver satisfaction, while clinical programs in regions such as Japan and Europe continue to progress.\nWe’ll now examine...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/why-neuren-pharmaceuticals-asxneu-is-up-63-after-record-dayb","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/why-neuren-pharmaceuticals-asxneu-is-up-63-after-record-dayb","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NEU.AU","NEU","BK7508","BK7096","BK4109"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632600110","title":"Softer Q1 Results and Cash Returns Could Be A Game Changer For NewMarket (NEU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2632600110","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632600110?lang=en_us&edition=fundamental","pubTime":"2026-05-03 21:23","pubTimestamp":1777814599,"startTime":"0","endTime":"0","summary":"NewMarket Corporation recently reported first-quarter 2026 results showing sales of US$669.72 million and net income of US$118.07 million, both lower than a year earlier, and its board declared a US$3.00 per-share dividend payable on July 1, 2026 to shareholders of record on June 15, 2026.\nAlongside these results, NewMarket completed a share repurchase of 337,201 shares for US$197.36 million, reducing its share count while continuing to return cash through dividends.\nWe’ll now examine how...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/2024000-choice2-main-header/1585186739035","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2024000-choice2-main-header/1585186739035"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/materials/nyse-neu/newmarket/news/softer-q1-results-and-cash-returns-could-be-a-game-changer-f","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/materials/nyse-neu/newmarket/news/softer-q1-results-and-cash-returns-could-be-a-game-changer-f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NEU.AU","BK7096","NEU","BK7508","BK4109"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139715255","title":"Stock Track | Neuren Pharmaceuticals Soars 5.12% Intraday as Daybue Stix Becomes Broadly Available in US","url":"https://stock-news.laohu8.com/highlight/detail?id=1139715255","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139715255?lang=en_us&edition=fundamental","pubTime":"2026-04-08 08:07","pubTimestamp":1775606846,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals Ltd (NEU.AU) saw its stock price soar 5.12% during intraday trading on Wednesday, following a significant commercial update for its key product.The sharp price increase is...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NEU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625523967","title":"BRIEF-Neuren Pharmaceuticals Says Daybue Stix Now Broadly Available In US For Rett Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2625523967","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625523967?lang=en_us&edition=fundamental","pubTime":"2026-04-08 08:07","pubTimestamp":1775606846,"startTime":"0","endTime":"0","summary":"BRIEF-Neuren Pharmaceuticals Says Daybue Stix Now Broadly Available In US For Rett SyndromeApril 8 (Reuters) - Neuren Pharmaceuticals Ltd NEU.AX:DAYBUE STIX NOW BROADLY AVAILABLE IN US FOR RETT SYNDROMEFurther company coverage: NEU.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nFWN40Q17W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","BK7508","NEU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625962474","title":"Neuren Pharmaceuticals Ltd - Daybue Stix NOW Broadly Available in US for Rett Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2625962474","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625962474?lang=en_us&edition=fundamental","pubTime":"2026-04-08 07:48","pubTimestamp":1775605691,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nFWN40Q17W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NEU.AU","BK7508","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620558425","title":"Vantage Foundation and Banking Academy of Vietnam Launch Nationwide AI Finance Programme with Vietnam's Top Universities for More Than 1,500 Students and Educators","url":"https://stock-news.laohu8.com/highlight/detail?id=2620558425","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620558425?lang=en_us&edition=fundamental","pubTime":"2026-03-17 18:29","pubTimestamp":1773743340,"startTime":"0","endTime":"0","summary":"HANOI, Vietnam, March 17, 2026 /PRNewswire/ -- Vantage Foundation, in collaboration with the Banking Academy of Vietnam  and more than 10 leading universities, has launched a nationwide programme equipping more than 1,500 educators and students with advanced skills in AI-driven financial data analysis and decision-making, drawing interest from more than 3,000 students nationwide.Held on 12 and 14 March at BAV's Hanoi campus, the initiative comes at a time when Vietnam's financial sector is rapidly strengthening its digital capabilities, with artificial intelligence playing an increasingly central role in financial analysis, risk management and strategic decision-making.The programme, titled \"Financial Data Analysis and Decision-Making in the Era of Artificial Intelligence \", combined in-person sessions with nationwide virtual participation.","market":"sh","thumbnail":"https://mma.prnewswire.com/media/2935764/image_5028204_30107511.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2935764/image_5028204_30107511.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/vantage-foundation-and-banking-academy-of-vietnam-launch-nationwide-ai-finance-programme-with-vietnams-top-universities-for-more-than-1-500-students-and-educators-302715882.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4109","AIYY","NEU.AU","BK4588","BK4587","BK4023","BK4528","BK4543","BK4551","BK4585","BK7096","BK7508","NEU","AI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620901504","title":"How Structural Oversupply In Petroleum Additives At NewMarket (NEU) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2620901504","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620901504?lang=en_us&edition=fundamental","pubTime":"2026-03-17 06:20","pubTimestamp":1773699630,"startTime":"0","endTime":"0","summary":"Recently, NewMarket Corporation has come under pressure as its core petroleum additives business faces structural oversupply, with global capacity additions outstripping demand and intensifying competition from Chinese exporters.\nAn additional concern for investors is that bearish research has highlighted how NewMarket’s heavy reliance on this challenged segment could weigh on overall profitability despite past diversification efforts.\nAgainst this backdrop, we’ll explore how persistent...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/2024000-choice2-main-header/1585186739035","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2024000-choice2-main-header/1585186739035"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/materials/nyse-neu/newmarket/news/how-structural-oversupply-in-petroleum-additives-at-newmarke","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/materials/nyse-neu/newmarket/news/how-structural-oversupply-in-petroleum-additives-at-newmarke","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","NEU.AU","BK7096","NEU","BK4109"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619121913","title":"Vantage Foundation and Banking Academy of Vietnam Launch Nationwide AI Finance Programme with Vietnam's Top Universities for More Than 1,500 Educators and Students","url":"https://stock-news.laohu8.com/highlight/detail?id=2619121913","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619121913?lang=en_us&edition=fundamental","pubTime":"2026-03-14 21:25","pubTimestamp":1773494700,"startTime":"0","endTime":"0","summary":"HANOI, Vietnam, March 14, 2026 /PRNewswire/ --Vantage Foundation, in collaboration with the Banking Academy of Vietnam  and more than 10 leading universities, has launched a nationwide programme equipping more than 1,500 educators and students with advanced skills in AI-driven financial data analysis and decision-making, drawing interest from more than 3,000 students nationwide.Held on 12 and 14 March at BAV's Hanoi campus, the initiative comes at a time when Vietnam's financial sector is rapidly strengthening its digital capabilities, with artificial intelligence playing an increasingly central role in financial analysis, risk management and strategic decision-making.A central component of the initiative was a Training-of-Trainers  programme designed to strengthen AI-driven financial analytics capabilities among lecturers. The faculty session attracted more than 250 professors who participated both in person and online. Among them were the dean and lecturers from Can Tho University, w","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/vantage-foundation-and-banking-academy-of-vietnam-launch-nationwide-ai-finance-programme-with-vietnams-top-universities-for-more-than-1-500-educators-and-students-302713926.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK7508","BK4528","AI","BK4023","NEU.AU","BK4551","BK4587","AIYY","BK4588","BK7096","NEU","BK4109","BK4543"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618604673","title":"Neuren Pharmaceuticals (ASX:NEU) Is Down 15.2% After 2025 Earnings Undershoot Expectations Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2618604673","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618604673?lang=en_us&edition=fundamental","pubTime":"2026-03-10 07:20","pubTimestamp":1773098455,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals Limited has reported its full-year 2025 results, with revenue of A$84.84 million and net income of A$30.44 million, both materially lower than the prior year’s levels.\nThe sharp reduction in basic earnings per share from continuing operations, from A$1.1117 to A$0.2373, highlights how recent financial performance contrasts with earlier analyst expectations for the business.\nWe’ll now examine how this sharp drop in annual revenue and earnings shapes Neuren...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-asxneu-is-down-152-after-2025-earning","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-asxneu-is-down-152-after-2025-earning","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NEU.AU","NEU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616137072","title":"Neuren's Royalties From Daybue Sales Beat Bull's Forecast -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2616137072","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616137072?lang=en_us&edition=fundamental","pubTime":"2026-03-04 07:08","pubTimestamp":1772579280,"startTime":"0","endTime":"0","summary":"2308 ET - Royalty revenue flowing to Neuren Pharmaceuticals from U.S. sales of the Daybue treatment for Rett Syndrome last year beat Macquarie's expectations. Acadia Pharmaceuticals, Neuren's partner, said U.S. net sales of Daybue totaled US$391 million in 2025. That was above the US$350 million of sales achieved in 2024. Macquarie says the sales outcome translates to A$65.0 million in royalties for Neuren, up 15% on year. This is 1.5% higher than its forecast of A$64.0 million. \"Royalty revenue ahead of expectations, driven by growth in new patient prescriptions,\" Macquarie says. \"Neuren's strong cash position enables pipeline acceleration, potentially providing significant long-term upside.\" It has an outperform call on Neuren. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEU.AU","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616346369","title":"Assessing Neuren Pharmaceuticals (ASX:NEU) Valuation After Its Latest Annual Earnings Reset","url":"https://stock-news.laohu8.com/highlight/detail?id=2616346369","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616346369?lang=en_us&edition=fundamental","pubTime":"2026-03-03 18:25","pubTimestamp":1772533526,"startTime":"0","endTime":"0","summary":"Earnings trigger and why Neuren is on radar\nNeuren Pharmaceuticals (ASX:NEU) has come into focus after releasing its full year 2025 results, reporting revenue of A$84.84 million and net income of A$30.44 million, both lower than the prior year.\nSee our latest analysis for Neuren Pharmaceuticals.\nThe share price reaction has been sharp, with a 1 day share price return of an 8.79% decline and a 30 day share price return of a 24.75% decline. The 1 year total shareholder return of 1.87% and 3...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/assessing-neuren-pharmaceuticals-asxneu-valuation-after-its","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/assessing-neuren-pharmaceuticals-asxneu-valuation-after-its","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NEU.AU","NEU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616925273","title":"BUZZ-Australia's Neuren Pharmaceuticals drops as US partner seeks EMA re-examination","url":"https://stock-news.laohu8.com/highlight/detail?id=2616925273","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616925273?lang=en_us&edition=fundamental","pubTime":"2026-03-03 11:53","pubTimestamp":1772510032,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neuren Pharmaceuticals drops as US partner seeks EMA re-examination** Shares of Neuren Pharmaceuticals NEU.AX fall 8% to A$12.67, on track for their weakest session since February 5** The biopharma firm says its partner, Acadia Pharmaceuticals ACAD.O, confirms plan to request re-examination of opinion adopted by Committee for Medicinal Products for Human Use of the European Medicines Agency ** Re-examination regarding the marketing of trofinetide for the treatment of Rett syndrome in patients two years and older - co** Australian healthcare stocks .AXHJ down 1.5%, in line with broader benchmark .AXJO which is down 1.2%** YTD, stock down 31.9%, including the day's move  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nL4N3ZR0BD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7096","LU2065169927.USD","LU2065170008.USD","LU2065171402.SGD","LU2065171311.SGD","BK4139","NEU.AU","ACAD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616609843","title":"Neuren Partner Plans to Request Re-examination of European Authority's Opinion on Trofinetide Marketing Authorization Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2616609843","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616609843?lang=en_us&edition=fundamental","pubTime":"2026-03-03 07:36","pubTimestamp":1772494615,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  said its partner, Acadia Pharmaceuticals, confirmed that it plans to request a re-examination of the European Medicines Agency's Committee for Medicinal Products for Human Use's opinion regarding the marketing authorization application for trofinetide for the treatment of Rett syndrome in patients aged two years and older, according to a Tuesday Australian bourse filing.The committee issued a refusal, saying that the treatment effect observed with trofinetide after 12 weeks, while measurable, was viewed as limited in magnitude, that the Lavender clinical trial did not capture all core symptoms of Rett syndrome, and that the assessment of longerterm outcomes was influenced by patient discontinuations over time.Trofinetide is approved in the US, Canada, and Israel, per the filing.Neuren Pharmaceuticals' shares fell 5% in early trading on Tuesday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","BK7508","NEU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616338779","title":"How Investors May Respond To Neuren Pharmaceuticals (ASX:NEU) 2025 Results, Buy-Back Plan And Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2616338779","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616338779?lang=en_us&edition=fundamental","pubTime":"2026-03-02 15:13","pubTimestamp":1772435590,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals recently reported its full-year 2025 results, with revenue of A$84.84 million and net income of A$30.44 million, alongside a trading pause on the ASX pending a market-sensitive announcement.\nDespite lower year-on-year earnings, Neuren highlighted increased DAYBUE royalties, a new share buy-back program, and progress in its NNZ-2591 pipeline, including an FDA Fast Track designation, underscoring the company’s focus on advancing its rare neurological disorder...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/how-investors-may-respond-to-neuren-pharmaceuticals-asxneu-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/how-investors-may-respond-to-neuren-pharmaceuticals-asxneu-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4211","BK7508","BK4109","NEU.AU","PRGS","BK4097","BK7096","ISBC","NEU","LU2065732104.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616804550","title":"Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2616804550","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616804550?lang=en_us&edition=fundamental","pubTime":"2026-03-02 12:27","pubTimestamp":1772425659,"startTime":"0","endTime":"0","summary":"An organic growth in Australian healthcare services is likely due to improving availability of bulk-billing general practitioners, offset by ongoing wage pressures, Jefferies said in a Monday report.I","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SHL.AU","BK7089","IMM.AU","FPH.AU","XAO.AU","BK7103","IDX.AU","XBI","XKO.AU","HLS.AU","COH.AU","CSL.AU","BK7126","ANN.AU","MVF.AU","BK4585","LABU","BK4588","BK7007","BK7501","BK7067","CU6.AU","NHF.AU","XLV","BK7511","BK7096","BK7508","BK7124","BK7509","BK4581","TLX.AU","BK7113","MSB.AU","CUV.AU","RHC.AU","HCAR","NEU.AU","XJO.AU","REG.AU","MPL.AU","SIG.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616447198","title":"Neuren Pharmaceuticals FY 2025 Margin Strength Tests Earnings Quality Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2616447198","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616447198?lang=en_us&edition=fundamental","pubTime":"2026-03-01 05:29","pubTimestamp":1772314142,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals (ASX:NEU) has opened FY 2025 with first half revenue of A$28.3 million and basic EPS of A$0.12, setting a different tone from the prior half, when the company recorded A$192.5 million of revenue and basic EPS of A$1.05. The company has seen revenue move from A$26.2 million and basic EPS of A$0.06 in the first half of FY 2024 to A$28.3 million and A$0.12 in the latest period. Trailing twelve month EPS sits at A$1.17 on revenue of A$218.9 million, giving investors a clear...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-fy-2025-margin-strength-tests-earning","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-fy-2025-margin-strength-tests-earning","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NEU.AU","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614060270","title":"Neuren Pharmaceuticals Says US Partner Reports Higher Q4 2025 Daybue Sales; Shares Up 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614060270","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614060270?lang=en_us&edition=fundamental","pubTime":"2026-02-26 12:03","pubTimestamp":1772078605,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  said its US partner Acadia Pharmaceuticals reported fourth-quarter 2025 Daybue net sales of $110 million, up 13% from a year earlier, according to a Thursday Australian bourse filing.Daybue, or trofinetide, is the company's oral Rett syndrome drug approved by the US Food and Drug Administration, Health Canada, and the Ministry of Health in Israel. The company granted Acadia an exclusive worldwide license to develop and commercialize trofinetide.Acadia expects 2026 Daybue net sales of $460 million to $490 million, implying royalty income to Neuren of AU$70 million to AU$77 million, per the filing.Neuren Pharmaceuticals' shares rose past 6% in recent Thursday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","BK7508","NEU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612287110","title":"Is Neuren’s 5 Percent Share Buyback Altering The Investment Case For Neuren Pharmaceuticals (ASX:NEU)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2612287110","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612287110?lang=en_us&edition=fundamental","pubTime":"2026-02-20 00:40","pubTimestamp":1771519229,"startTime":"0","endTime":"0","summary":"On 11 February 2026, Neuren Pharmaceuticals Limited (ASX:NEU) announced a share repurchase program authorizing the buyback and cancellation of up to 6,350,631 shares, or 5% of its 126,639,526 issued shares, with the program running until 2 March 2027.\nThis move reduces the future share count relative to current levels, which can increase each remaining share’s claim on any future earnings and cash flows.\nWe’ll now examine how Neuren’s decision to buy back and cancel up to 5% of its shares...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/is-neurens-5-percent-share-buyback-altering-the-investment-c","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/is-neurens-5-percent-share-buyback-altering-the-investment-c","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NEU.AU","BK7096","NEU","BK4109","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":46,"code":"91000000","status":"200"}]}}